Chief Scientific Officer, Professor, Dr. of Sci. Central Institute for Tuberculosis Research (Moscow, Russia). Professor Apt is an internationally acclaimed expert in the field of experimental TB immunogenetics. His scientific interests are focused on immunology and immunogenetics of experimental TB and other infections. Professor Apt developed a number of new models of experimental TB facilitating and proving host multi-gene control of TB progression. He studied the role of H2 genes in control of TB infection in mice. Three loci controlling host susceptibility in mice were identified in prof. Apt's lab, and a number of related genes were cloned. Prof. Apt's lab is one of the world leading research groups focused on TB genetics. Professor Apt is member of editorial boards of several journals, including Tuberculosis and Tuberculosis Research and Treatment.
Valeria S. Velezheva, PhD
Chief chemist, Professor, Dr. of Sci. A.N.Nesmeyanov Institute of Organoelement Compounds (RAS). Professor Velezheva possesses broad experience in organic synthesis and construction of biologically active compounds. Her team is focused on development of new methods of organic synthesis, including design of new reactions that are used for medical drugs synthesis, re-design and optimization.
Boris V. Nikonenko MD/PhD
Director of preclinical studies, Dr. Sc. Dr. Nikonenko's professional interests and expertise are in the field of immunology and genetics of experimental TB and other mycobacterial infections. Testing of anti-TB vaccines and drug candidates. Together with colleagues he mapped 3 TB-related loci in mouse genome, elucidated the role of a number of murine genes in TB resistance and immunity. As Chief Scientist and Director of Animal Studies for 12 years (2001-2013) he played major role in anti-TB drugs development at Sequella Inc. (Rockville, MD), testing drug candidates against Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium abscessus and Candidae spp. in mouse models.
Peter E. Gaidar
Chief Executive Officer. Mr. Gaidar is a seasoned executive with broad experience in various fields. Prior to TB-Stopper Mr. Gaidar held executive positions in a number of Russian companies focused on banking, development and cinema industry.
Konstantin A. Kazarian, PhD
Development Director. Dr. Kazarian is an experienced Development Director with strong scientific background in international environment. Dr. Kazarian is a California based professional working in the field of new drug development where science and industry meet to create innovative cures. Areas of expertise: Management of live sciences and high-tech related projects and events, Business development in pharmaceutical and biotech industries, Forming of result-oriented teams, Pharmaceutical manufacturing (GMP), Vaccine development, Biochemistry of TB, cancer and Alzheimer's disease. Dr. Kazarian held a number of research and managing positions in academia and industry in Russia, Italy and US.